Hepatitis B e Antigens

A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G.

Also Known As:

Networked: 4130 relevant articles (356 outcomes, 555 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kao, Jia-Horng: 63 articles (05/2015 - 01/2002)
2.	Lai, Ching-Lung: 51 articles (04/2015 - 07/2002)
3.	Janssen, Harry L A: 46 articles (07/2015 - 03/2004)
4.	Marcellin, Patrick: 44 articles (09/2015 - 01/2002)
5.	Chen, Ding-Shinn: 42 articles (04/2015 - 01/2002)
6.	Liaw, Yun-Fan: 41 articles (06/2015 - 01/2002)
7.	Chen, Pei-Jer: 41 articles (05/2015 - 01/2002)
8.	Yuen, Man-Fung: 38 articles (04/2015 - 11/2002)
9.	Kumada, Hiromitsu: 33 articles (01/2015 - 01/2002)
10.	Suzuki, Fumitaka: 33 articles (01/2015 - 01/2002)

Related Diseases

1.	Chronic Hepatitis B 01/01/2009 - "Responses in HBeAg-negative chronic hepatitis B were very high during treatment but high relapse rates eliminated most of the long-time treatment effect. " 02/01/2013 - "In HBeAg-negative genotype D patients with chronic hepatitis B, PegIFN treatment for 96 weeks was well tolerated and the post-treatment virological response improved significantly compared with 48 weeks of treatment. " 01/01/2009 - "In conclusion, peginterferon-alpha-2a (40 kD) is a valuable option for the first-line treatment of HBeAg-negative or -positive chronic hepatitis B." 06/01/2007 - "This observation may help to develop better clinical management in HBeAg-negative chronic hepatitis B patients." 01/01/2009 - "These findings suggest that 9 microg CIFN is effective in the treatment of patients with HBeAg-positive chronic hepatitis B. "
2.	Hepatitis B 06/01/2012 - "Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission." 11/01/2009 - "This study shows that mean hepatic stiffness by elastography is significantly lower in patients with inactive hepatitis B compared to those with HBeAg-negative disease. " 12/01/1991 - "Other studies demonstrated that the mutant forms were observed with increasing frequency during the successful conversion from HBeAg positivity to anti-hepatitis B e antibody (anti-HBe) positivity. " 07/01/2015 - "Detection of hepatitis B activity in HBeAg-negative carriers with normal aminotransferase levels in central Brazil." 02/01/2015 - "Correlation Between Hepatitis B G1896A Precore Mutations and HBeAg in Chronic HBV Patients."
3.	Infection 07/01/2011 - "The knowledge of the natural history of chronic HBV infection in Euro-Mediterranean and African countries combined with wide screening programs for prompt recognition and treatment of chronic HBV infection both in its HBeAg-positive and -negative immune reactive phases can be expected to increase the efficacy of current and future therapeutic strategies." 04/01/2010 - "Moreover, current treatment approaches have their limitations: although IFN-alpha has been shown to be effective in patients with non-vertically-transmitted infection, HBeAg clearance while on treatment is similar to spontaneous seroconversion after long-term follow-up. " 09/01/2004 - "In conclusion, the clearance of HBeAg from serum may occur by different mechanisms in HBV/Aa, HBV/Ae, and HBV/D infections, which may influence clinical manifestations in the Western countries where both genotypes A and D are prevalent." 06/01/1991 - "We assessed the efficacy of a government-sponsored mass protection program in Osaka, Japan, for perinatal HBV infection in infants born to HBeAg positive HBV carrier mothers. " 01/01/1991 - "In a follow-up study of 16 HBeAg-positive patients with HDV infection, eight (50%) cleared HBeAg and three (18.8%) seroconverted to anti-HBe within 3 months. "
4.	Fibrosis (Cirrhosis) 07/01/2003 - "Multivariate analysis showed that difference in HBV genotype influenced significantly either the clearance of HBeAg or the development of cirrhosis. " 09/01/2007 - "The rate of fibrosis progression was lower in patients with sustained disease remission than in those who remained HBeAg positive (median 0 fibrosis units/year, range -2.00 to -0.70 fibrosis units/year, versus median 0.51 fibrosis units/year, range 0 to +2.03 fibrosis units/year, P = 0.02). " 07/01/2003 - "In conclusion, HBeAg was cleared from sera more frequently and earlier in patients with genotype B compared with those with genotype C, and development of cirrhosis occurred less frequently in patients with genotype B compared with those with genotype C. " 02/01/2010 - "Neucleot(s)ide analogues are effective in suppressing HBV replication in patients with HBeAg-negative cirrhosis, but the impact of which on the mortality and complications of cirrhosis should be prolongly observed. " 08/01/2007 - "PEG-IFN is effective and safe for HBeAg-positive patients with advanced fibrosis. "
5.	Liver Diseases (Liver Disease) 10/01/2012 - "In a country with considerable amount of active CHB patients, monotherapy with a highly potent third generation drug has the most health-gain, and is cost-effective in both HBeAg-positive and negative in all stages of liver disease." 01/01/1995 - "We now show that the number of amino acid substitutions in the HBV core is low in viral sequences from patients with HBeAg positive chronic liver disease and HBeAg negative HBeAb positive patients in remission, but the frequency of substitutions is high in HBeAg, negative HBeAb positive patients with active liver disease. " 09/01/2006 - "Courses of finite duration, aiming to achieve sustained off-therapy responses, are practically restricted to HBeAg+ patients with compensated chronic liver disease, whereas long-term therapy aiming to achieve maintained on-therapy remission is mostly applicable to HBeAg- individuals either with early or advanced liver disease. " 07/01/1996 - "Conversely about 90% of children infected later in life clear HBeAg and achieve sustained remission of liver disease before reaching adulthood. " 03/01/2007 - "These will be followed eventually by HBeAg seroconversion, which is usually accompanied by remission of liver disease and confers favourable outcome. "

Related Drugs and Biologics

1.	Antigens
2.	DNA (Deoxyribonucleic Acid)
3.	Lamivudine (3TC)
4.	Hepatitis B Surface Antigens (HBsAg)
5.	Interferons
6.	Interferon-alpha (Interferon Alfa)
7.	entecavir
8.	adefovir dipivoxil (Hepsera)
9.	Alanine Transaminase (SGPT)
10.	telbivudine

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Cryosurgery
3.	Aftercare (After-Treatment)
4.	Liver Transplantation
5.	Retreatment